Simplex Trading, LLC Enlivex Therapeutics Ltd. Call Options Transaction History
Simplex Trading, LLC
- $156 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ENLV
# of Institutions
30Shares Held
3.18MCall Options Held
44.3KPut Options Held
7.1K-
Armistice Capital, LLC New York, NY1.78MShares$1.82 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny669KShares$682,3880.0% of portfolio
-
Morgan Stanley New York, NY231KShares$235,2980.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny181KShares$184,9140.0% of portfolio
-
Jane Street Group, LLC New York, NY80.8KShares$82,3740.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $18.8M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...